findmyKOL
Clinical trialNCT05809635RecruitingObservational

Study of BEST1 Vitelliform Macular Dystrophy

SponsorColumbia UniversityEnrollment52Best Vitelliform Macular DystrophyRetinitis Pigmentosa
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France
  • Institut de la Vision/centre de Maladies Rares Du Centre Hospitalier National Ophtalmologique Des Quinze-Vingts

    Paris, France

    Isabelle Audo, MD, PhD
    Not, yet, recruiting
Germany
  • Eberhard Karls University Tubingen

    Tübingen, Germany

    Eberhart Zrenner, MD
    Recruiting
United States
  • Columbia University Irving Medical Center

    New York, New York, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Mar 2021
Primary completion
31 May 2026
Completion
31 May 2026
Last update posted
30 Jul 2025
Registered enrollment
52
Registry id
NCT05809635

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.